Tiziana life sciences announces publication in proceedings of the national academy of sciences (pnas) illustrating the immunological basis of the mechanism of action for intranasal foralumab

New york, march 08, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a publication in the preeminent1 journal, proceedings of the national academy of sciences (pnas), that illustrates the immunological basis of the mechanism of action (moa) for intranasal foralumab. a copy of the article can be found at pnas.org.2
TLSA Ratings Summary
TLSA Quant Ranking